|
15 Oct 2019 |
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
|
|
15 Oct 2019 |
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
|
|
15 Oct 2019 |
U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
|
|
15 Oct 2019 |
Affimed Reports Progress on Key Clinical Development Programs
|
|
15 Oct 2019 |
Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults
|
|
15 Oct 2019 |
Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
|
|
15 Oct 2019 |
AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
|
|
15 Oct 2019 |
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
|
|
15 Oct 2019 |
Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer
|
|
15 Oct 2019 |
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology
|
|
15 Oct 2019 |
Immutep reports positive final efficacy data from TACTI-mel trial in melanoma
|
|
15 Oct 2019 |
Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s Ataxia
|
|
15 Oct 2019 |
Enterprise Therapeutics Awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator
|
|
14 Oct 2019 |
Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis
|
|
14 Oct 2019 |
Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders
|
|
14 Oct 2019 |
I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China
|
|
14 Oct 2019 |
U.S. FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
|
|
14 Oct 2019 |
DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease
|
|
14 Oct 2019 |
Femtogenix Presents Efficacy and Toxicity Data on Antibody Drug Conjugates Containing New Generation of DNA-binding Therapeutic Payloads
|
|
14 Oct 2019 |
Phase III PEMPHIX Study Shows Genentech’s Rituxan (Rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
|
